Japan Re-approves Thalidomide For Cancer Treatment
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's Ministry of Health, Labor and Welfare has approved re-listing thalidomide, which Japan banned in 1962 for causing serious human deformations, to be marketed by Fujimoto Pharmaceutical, officials of the ministry's Pharmaceutical and Food Bureau and the Insurance Bureau confirmed Oct. 7
You may also be interested in...
Japan To List Nine Composites For National Health Insurance Coverage
TOKYO - At its Dec. 3 plenary meeting, Chuikyo (the Central Social Insurance and Medical Council), the government-private body that sets Japan's medical and pharmaceutical policies, approved the listing of nine composites for 13 pharmaceutical products, including the relisting of Fujimoto's Thaled (thalidomide) for multiple myeloma
Japan To List Nine Composites For National Health Insurance Coverage
TOKYO - At its Dec. 3 plenary meeting, Chuikyo (the Central Social Insurance and Medical Council), the government-private body that sets Japan's medical and pharmaceutical policies, approved the listing of nine composites for 13 pharmaceutical products, including the relisting of Fujimoto's Thaled (thalidomide) for multiple myeloma
Japan’s Ministry Reviews Thalidomide For Multiple Myeloma
The Ministry of Health, Labor and Welfare began a review panel meeting Aug. 26 to consider thalidomide as a treatment for multiple myeloma, on condition that adverse event prevention methods are fully addressed. The MHLW panel will consider safety measures put forth by pharmaceutical companies, such as registration requirements for pharmacists, physicians and patients and establishment of a third party to monitor compliance. Upon completion of the review the drug could be launched as early as the end of the year. Japan has 13,000-14,000 multiple myeloma patients. Thalidomide is approved to treat multiple myeloma in 17 countries. (Click here for more - Japanese language)